Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495387 | 0.89 | KMT2A (0.45) | TDP1MEN1KMT2AMAPTSRD5A2 | |
| SCHEMBL29071444 | 0.82 | ACP3 (0.48) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL8408254 | 0.82 | ALDH1A1 (0.43) | TDP1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14703649 | 0.79 | MGLL (0.48) | MEN1KMT2AMAPTSRD5A2ALDH1A1 | |
| SCHEMBL2886387 | 0.78 | CYP2C19 (0.43) | TDP1KMT2AALDH1A1HPGDCES1 | |
| SCHEMBL15288279 | 0.78 | ALDH1A1 (0.42) | TDP1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28701229 | 0.77 | ALDH1A1 (0.41) | TDP1MEN1KMT2AMAPTSRD5A2 | |
| SCHEMBL28450136 | 0.77 | CYP2C19 (0.45) | MEN1KMT2ATGM2CES1CES2 | |
| SCHEMBL4660421 | 0.76 | TDP1 (0.44) | TDP1MAPTALDH1A1HPGDCA1 | |
| SCHEMBL5603510 | 0.76 | ALDH1A1 (0.39) | TDP1MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113968823-A | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | 麻省理工学院 | 2022-01-25 | — | — | CN | disclosed |
| CN-107848988-B | Alkenyl substituted 2, 5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | 麻省理工学院 | 2021-10-22 | — | — | CN | disclosed |
| CN-112386604-A | Modulators of cGAS | 纪念斯隆-凯特琳癌症中心 | 2021-02-23 | — | — | CN | disclosed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | disclosed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | disclosed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | TDP1 2764/4885MEN1 4773/4885KMT2A 3680/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | TDP1 2764/4885MEN1 4773/4885KMT2A 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.